More than 200 heterozygous mutations in the type 2 BMP receptor gene, BMPR2, have been identified in patients with Heritable Pulmonary Arterial Hypertension (HPAH). More severe clinical outcomes occur in patients with BMPR2...
Obesity is accompanied by numerous systemic and tissue-specific derangements, including systemic inflammation, insulin resistance, and mitochondrial abnormalities in skeletal muscle. Despite growing recognition that adipose...
Bone morphogenetic proteins (BMPs) constitute the largest subdivision of the transforming growth factor-? family of ligands. BMPs exhibit widespread utility and pleiotropic, context-dependent effects, and the strength and...
The bone morphogenetic protein (BMP) type 2 receptor ligand, Bmp2, is upregulated in the peripheral pulmonary vasculature during hypoxia-induced pulmonary hypertension (PH). This contrasts with the expression of Bmp4, which is...
The transforming growth factor ? (TGF-?) superfamily is a large group of signaling molecules that participate in embryogenesis, organogenesis, and tissue homeostasis. These molecules are present in all animal genomes....
The COVID-19 pandemic has highlighted the need for additional health precautions in medically fragile populations. COVID-19 is a respiratory virus demonstrating increased mortality in individuals with risk factors such as...
Successful fracture healing requires the simultaneous regeneration of both the bone and vasculature; mesenchymal stem cells (MSCs) are directed to replace the bone tissue, while endothelial progenitor cells (EPCs) form the new...
Bone morphogenetic protein (BMP) signaling has been linked to the development of pulmonary hypertension (PH). Inhibitors of differentiation (ID) proteins (ID1-4) are a family of basic helix-loop-helix transcription factors that...
Patients with familial pulmonary arterial hypertension inherit heterozygous mutations of the type 2 bone morphogenetic protein (BMP) receptor BMPR2. To explore the cellular mechanisms of this disease, we evaluated the pulmonary...
Ferric citrate (FC) is an approved therapy for chronic kidney disease (CKD) pa-
tients as a phosphate (Pi) binder for dialysis-dependent CKD, and for iron de-
ficiency anemia (IDA) in non-dialysis CKD. Elevated Pi and IDA...